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Summary
Background: Information on long-term follow-up of children
and adolescents treated for intracerebral germ-cell tumour is
scant. We report on the results of a small series of patients
treated at a single institution.
Patients and methods: Hospital records from 15 patients
treated between 1980 and 1998 were reviewed. An attempt was
made to correlate sequelae to tumour location and treatment
modalities.
Results: This cohort constitutes 5.5% of all brain tumours
diagnosed at our institution. Histology: 10 germinomas, 2 be-
nign teratomas, 2 malignant teratomas, and one mixed germ-
cell tumour. Overall survival was 87%, with a mean follow-up
time of 7 years and 8 months. The majority of patients have
long-term sequelae involving one or several organ systems. In
66% endocrine, in 47% ophthalmologic, in 60% neuropsycho-
logical defects were observed. Endocrine and ophthalmologic
sequelae show a correlation to tumour location. Neuropsycho-
logical long-term abnormalities are frequent and are associated
with cranial irradiation in particular at young age, but less with
tumour location, irradiation dose or surgery.
Conclusions: Our preliminary data suggest that today intra-
cerebral germinomas and mature teratomas have a good prog-
nosis even when a relapse occurs. The outcome for mixed
germ-cell tumours and malignant teratomas is less favourable.
Although long-term sequelae are present in the majority of
patients, there is some evidence that patients treated after 1990
suffer fewer severe long-term defects, thereby indicating that
recent treatment protocols may result in a reduction of sequelae.
Key words: endocrine, germ-cell tumour, germinoma, long-
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Abbreviations: CNS - central nervous system; CSF - cerebro-
spinal fluid; GCT - germ-cell tumour; GCTC - germ-cell
tumours of the CNS; AFP - alpha fetoprotein; PHCG - beta
human chorionic gonadotropin; TRH - thyrotropin releasing
hormone; FT4 - free and total thyroxine; T3 - total
trijodothyronin; FSH - follicle stimulating hormone; LH -
luteinizing hormone; ACTH - adrenocorticotropin hormone;
GH - growth hormone; IGF - insulin-like growth factor.
Introduction
Primary germ-cell tumours of the CNS (GCTC) are
rare, representing only l%-3.4% of all paediatric brain
tumours in western countries [1-4]. A higher incidence
is reported from Japan, where GCTC account for 5%-
15% of paediatric brain tumours [2, 5].
Approximately 90% of GCTC afflict patients younger
than 20 years, with a peak incidence occurring between
the ages of 10-12 years [1, 5]. According to the
WHO classification [6], GCTC can be divided into five
histological subtypes: Germinoma (or dysgerminoma),
teratoma, yolk sac tumour, embryonal carcinoma and
choriocarcinoma. GCT in general have a preferential
midline location and GCTC occur mainly in the pineal
or suprasellar region. Their location explains the charac-
teristic clinical manifestations: patients with suprasellar
tumour typically present with diabetes insipidus, hypo-
pituitarism and visual symptoms while hydrocephalus,
Parinaud syndrome and precocious puberty are typically
seen in patients with pineal tumours.
Oncofetal antigens are of some limited value as
markers for histological differential diagnosis in pineal
or suprasellar tumours. AFP and (3HCG levels in serum
and CSF are useful to determine histological subtypes
and therapeutic response but are of restricted value in
predicting prognosis [3, 4, 7].
In the last decade advances in neurosurgical proce-
dures, craniospinal radiotherapy and adjuvant chemo-
therapy have made paediatric GCTC a potentially curable
disease. In patients with germinoma a five-year survival
rate of over 90% has been reported with irradiation and
adjuvant chemotherapy [2-4, 8]. Yolk sac tumours,
embryonal carcinomas and choriocarcinomas are less
sensitive to irradiation and had a poor prognosis in
the past. However, new treatment strategies including
cisplatin or carboplatin based chemotherapy have re-
sulted in either longer remission duration or increased
cure rate [2, 3].
We have studied the outcome and long-term sequelae
in patients with GCTC treated in our institution, aspects
which have only been sparsely reported in children
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Table 1. Characteristics of 15 patients with GCTC.
Age (years)
Median 113/12
Range 2 10/12-16 11/12
Sex («)
Male 10
Female 5
Histology
Germinoma 10
Benign teratoma 2
Malignant teratoma 2
Mixed germ-cell tumor 1
Localisation
Multifocal (=pineal and hypothalamic region/
third ventricle) 6
Pineal region only 3
Hypothalamic or suprasellar region only 4
Middle cranial fossa 1
Mesencephalon and third ventricle 1
Leptomeningeal dissemination (in CT/MRI
and/or CSFanalysis) 8
Tumor markers
Normal range (AFP 0-20 U/ml,
(3HCG 0-5 U/ml) 8
AFPf (21-97 U/l) 2
(3HCGT (22.2-711 U/ml) 4
PHCGT (2499 U/l)+ AFPf (385 U/ml) 1
treated with modern protocols. In addition we tried to
evaluate the effects of newer protocols that are stratified
more specifically against different histological types and
which better respect potential radiotoxicity.
Table 2. Symptoms at presentation.
Symptom Affected patients (n = 15)
Nausea and vomiting
Severe headache
Diabetes insipidus
Chronic fatigue
Chronic weight loss
Symptoms of hemiparesis
Ophthalmologic symptoms
Abnormal eye movements
Diplopia
Complete Pannaud syndrome
Decreased visual acuity
Visual field defect
Ptosis
Pilloedema
10
9
8
5
4
3
repeated measuring of specific weight of urine, serum and urine
electrolytes. As several patients required hormone substitution after
therapy end, we did not suspend substitution to perform endocrino-
logical follow-up testing.
Neurological and neuropsychological evaluation
Repeated neurological exams were performed in all patients. Nine
patients had neuropsychological evaluation by trained psychologists.
All patients and parents were interviewed about schooling outcome
(determined as coping/non coping with age related schooling perfor-
mance), social activity and behaviour before and after treatment for
GCTC.
Patients and methods
From July 1980 to December 1998, 272 children were newly diagnosed
with a brain tumour in our institution. Of these, 15 patients were
diagnosed and treated for GCTC (5.5% of all brain tumours) and were
followed until July 1999. Observation period was 16-228 (mean 91)
months. Inclusion was restricted to patients who had confirmed histo-
logical or cytological diagnosis according to WHO classification,
radiological evaluation (CTscan and/or MRI) and analysis of tumour
markers (serum AFP and PHCG).
The patients' characteristics and symptoms at presentation are
shown in Tables 1 and 2. Data were collected during treatment and
regular follow-up and reviewed by the authors. Patients were evaluated
for remission status, endocrine dysfunction, neurological and neuro-
psychological sequelae. Growth, weight, evaluation of bone age and
secondary sexual characteristics (Tanner stages) were measured re-
peatedly in all patients.
Endocrine function tests
Evaluation in our patients was started at time of initial presentation
and was completed during follow-up after treatment. Evaluation for
endocrinological dysfunction consisted of the following tests:
TSH, FT4 and T3 were measured repeatedly in all patients. GH
and IGF was monitored in 10 patients, LH, FSH. testosteron, oestra-
diol, ACTH, basal cortisol in 9 patients and prolactin in 6 patients,
respectively. The following functional hormone tests were carried out:
gonadal-releasing-hormone-test in six, arginin- and insulin-tolerance
test in four and TRH test in three children, respectively. Normal values
were determined according to age specific range given by the labora-
tory-. Posterior pituitary function was evaluated in all patients by
Statistical methods
The Kaplan and Meier survival method [9] was used to calculate the
overall survival and progression-free survival. Overall survival was
calculated from date of diagnosis until date of last follow-up or death
for any cause. Progression-free survival was calculated from date of
end of therapy to date of last follow-up, first relapse or death.
Results
Therapy outcome (see Table 3 and Figures 1 and 2)
The overall survival rate in the 15 patients is 87%
(germinoma 90%) with a mean follow-up of 77 months
after end of treatment. Two patients have died; one
patient (case AF) died fourteen months after end of
therapy due to acute infarction of the left middle cere-
bral artery. At autopsy no evidence of tumour relapse was
found. The aetiology remained unclear, an overwhelming
virus encephalitis was supposed. Another patient with a
mixed germ-cell tumour (case WM) died of tumour
progression after relapsing four months after end of
treatment.
Tumour relapses: in addition to the above mentioned
there were two further patients who suffered a relapse.
One germinoma patient (case RM) had a first relapse in
the cervical, thoracic and lumbar spine 12 months after
diagnosis. Chemotherapy (MAHO 94) and irradiation
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Table 3. Individual clinical characteristics, treatment and outcome of all patients.
Patient
(born)
AF
(1970)
JC
(1980)
SK
(1969)
DS
(1977)
HC
(1977)
LM
(1982)
MF
(1977)
RM
(1979)
TS
(1983)
LJ
(1981)
WM
(1974)
ZT
(1974)
EM
(1984)
WA
(1984)
GR
(1988)
Year of diagnosis,
histology
1980. germinoma
1983, germinoma
1985, germinoma
1988. germinoma
1993, germinoma
1994, germinoma
1994, germinoma
1994, germinoma
1997, germinoma
1997, germinoma
1987, mixed
germcell-tu.
Multicystic dermoid
1980
Malignant teratoma
1988
1997, malignant
teratoma
1985, benign
teratoma
1994, benign
teratoma
Tumour location
Multifocal
Pineal
Multifocal
Hypothalamic
Pineal metastases in
third ventricle
Pineal
Multifocal
Hypothalamic spinal
dissemination
Multifocal
Hypothalamic
Hypothalamic
Mesencephalon third
ventricle
Multifocal
Middle cranial fossa
Pineal
Tumour
marker
elevated
-
AFP
-
PHCG
-
PHCG
pHCG
-
AFP
and
PHCG
PHCG
only at
second
relapse
AFP
-
-
Surgery
VP-shunt
VP-shunt
Partial
resection
VP-shunt
VP-shunt
Partial
resection
Total
resection
VP-shunt
Partial
resection
VP-shunt
Biopsy
Biopsy
VP-shunt
Total
resection
VP-shunt
Total
resection
VP-shunt
Partial
resection
Total
resection
Total
resection
Chemotherapy
-
VAC 1980
-
VAC 1980 not
accomplished
MAKEI 89
-
MAKEI 89
1. MAKEI 89
2. MAHO94
3. 3 x VP16-Ifo-
cisplatin
4. High-dose che-
motherapy
SIOP GCT 96
-
Einhorn-protocol for
malignant teratoma
Only at
2. Relapse: VAC
SIOP GCT 96
-
-
Radiation therapy,
brain + tumour-
boost
55 Gy
30 + 20 Gy
52 Gy
39+ 15 Gy
Spinal: 30 Gy
30+ 15 Gy
Spinal' 30 Gy
35+ 18 Gy
Spinal: 35 Gy
21 +20Gy
Spinal: 21 Gy
1. 25 + 16Gy(no
spinal radiation)
2. Spinal 30 Gy
3. Filum terminale
20 Gy
24+16Gy
Spinal: 24 Gy
24+ 16 Gy
Spinal: 24 Gy
Only at relapse: 30 +
16 Gy
30 Gy spinal
Only at second
relapse: 30+ 15 Gy
30 + 24 Gy
Spinal1 30 Gy
-
-
Remission
duration
Died after 14
months
First remission
180 months
First remission
218 months
First remission
131 months
First remission
71 months
First remission
57 months
First remission
54 months
First + second +
third remission
27 months
First remission
19 months
First remission
18 months
Died after 16
months
First + second +
third remission
109 months
First remission
17 months
First remission
174 months
First remission
59 months
of the spine (from C2 to S2) with 30 Gy was given. A
second relapse in the conus medullaris region occurred
29 months after initial diagnosis and was treated with
chemotherapy including high-dose treatment (carbo-
platin and vepesid), autologous stem-cell transplantation
and radiotherapy of the conus medullaris. The patient is
currently in complete remission 27 months after end of
treatment. A further patient (case ZT) was originally
diagnosed 1980 with a benign multicystic dermoid in the
third ventricle. Ninety-two months after the initial diag-
nosis he developed a malignant teratoma in the recessus
infundibularis. Again, thirteen months after resection of
this tumour, a local relapse occurred. A third remission
was achieved following combined radiation- and chemo-
therapy. PHCG was elevated only at second relapse. One
hundred nine months later he is in continuous complete
remission.
Direct therapy associated morbidity
Neurosurgery
All 15 patients had either biopsy, partial or total tumour
resection, ventriculo-peritoneal-shunt insertion or a
combination of procedures. There was no associated
mortality. One patient (WA) was operated at the age of
six weeks because of a mature teratoma of the right
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Figure 1. Kaplan-Meier analysis for progression-free survival in 15
patients with intracerebral germ-cell tumour. Analysis separately for
germinoma (ft = 10) and all other histologies (ft = 5).
0,2-
0,0.
96 144 192
Overall survival (monlhs)
Figure 2. Kaplan-Meier analysis for the overall survival in 15 patients
with intracerebral germ-cell tumour.
middle cranial fossa. After surgery she had left sided
paresis of facial and hypoglossus nerves which persisted.
In two patients Parinaud syndrome was observed
only after neurosurgical intervention.
Shunt complications occurred in one of nine patients:
Patient MF presented with meningitis due to clostridium
diphteriae two months after insertion of a ventriculo-
peritoneal shunt. Subsequently, three months later, he
developed acute abdominal pain which was caused by
a perforation of the distal part of the shunt into the
duodenum. No peritoneal metastases have been ob-
served.
Radiation therapy
Postactinic neuronal dysfunctions were found in two
patients. One child, irradiated 1983 at the age of 2 10/12
years (patient JC) with 30 Gy to the whole brain and 20
Gy tumour boost, presented with ataxia only during the
first year after radiotherapy. A 16-year-old adolescent
treated according to the MAKEI 89 protocol developed
spastic hemiplegia due to leukencephalopathy four
months after radiotherapy with 20 x 1.5 Gy to the whole
brain including spinal axis and 14 Gy tumour boost. He
has residual findings of hemiparesis six years after the
end of treatment.
Chemotherapy
One patient had severe gastrointestinal bleeding with
acute abdomen and bowel obstruction under VAC-
chemotherapy. There were no other severe infectious or
bleeding complications reported. During long-term
follow-up patients treated with cisplatin based chemo-
therapy showed no detectable hearing deficit on audio-
gramm or laboratory signs of impaired renal function.
Long-term follow-up
Ophthalmologic symptoms
At presentation nine patients had abnormal eye move-
ments. Complete Parinaud syndrome was found in six
patients. Four patients had decreased visual acuity and
three patients showed visual field defects.
At the last follow-up, six children had persisting eye
movement abnormalities. Complete Parinaud syndrome
was found in five cases. Two patients had a restricted
visual field and in four children a reduced visual acuity
was found. One adolescent girl presented with headache
and reduced visual acuity of the right eye. The initial
MRI showed a tumour infiltrating the optic nerve near
the chiasm. Her visual acuity decreased rapidly and 14
months after the end of therapy (cranial and spinal
radiotherapy with 24 Gy and tumour boost of 16 Gy,
fractionated into 25 doses of 1.6 Gy) she was blind on
the right eye and had a visual acuity of 0.4 in the left eye.
Endocrine abnormalities
In nine patients (age 2 10/12-16 11/12 years; eight
germinomas and one malignant teratoma) clinical and
laboratory signs of endocrine dysfunction were found.
Eight patients had already diabetes insipidus on
admission, which persisted at follow-up. All had tumour
infiltration of the hypothalamus. Seven patients developed
persistent panhypopituitarism. All had received radio-
therapy with 40-55 (mean 46) Gy to the tumour region,
fractionated into doses of 1.6-2 Gy.
GH deficiency was found in seven patients, but only
in three patients decreased growth rate was documented
and GH was substituted. In these patients radiation
therapy was given at the age of 3, 11, and 14 1/2 years,
respectively, with 40, 50 and 52 Gy total tumour dose,
fractionated into doses of 1.8-2 Gy. At the time of the
last visit all patients had body height above the 10th
percentile.
Increased prolactine secretion (21-1310 mU/ml) was
found in six children with hypothalamic or multifocal
tumour. Two had initial tumour resection and in all
radiation therapy had been applied (40-54 total tumour
dose, fractionated into doses of 1.6-2 Gy/d). All six
patients also had hypogonadism and decreased FSH
and LH levels.
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One patient (case JC), who received focal radiation
therapy in 1983 (50 Gy total tumour dose, fractionated
into 25 doses of 2 Gy) for germinoma of the pineal
region at the age of 2 10/12 years, showed thyroid
dysfunction, growth hormone deficiency and subnormal
FSH not before 10 years after therapy completion.
Six out of fifteen children had no endocrine dysfunc-
tion at last follow-up and showed normal growth and
normal bone age. This includes both patients with a
mature teratoma who were treated with tumour resection
alone, 1 patient who died 6 months after radiotherapy
for tumour relapse and 1 patient with a malignant
teratoma of the pineal gland who is in first remission 17
months after partial tumour resection and radiotherapy
with 30 Gy and 24 Gy tumour boost (dose per fraction
1.5-1.6 Gy). Two patients were followed for 57 and 71
months. Both had resection of a pineal germinoma and
radiation therapy with a dose of 53 Gy (fractions of 1.6-
1.8 Gy) and 45 Gy (fractions 30 x 1.5 Gy) at an age of
12 and 16 years, respectively.
Neuropsychological sequelae
Nine patients underwent neuropsychological evaluation
14-157 months after the end of treatment. They had
undergone radiation therapy at an age of 2 10/12-
16 11/12 (mean age 10 5/12 years), with total tumour
doses of 40-52 Gy. Eight children received additional
chemotherapy and five had partial or total tumour
resection. All nine patients had mild to severe difficulties
to cope with schooling demands. All were 'slower' and
had attention deficits in comparison to their healthy
peers. Three patients had fine motor dysfunctions, two
patients had disturbed spatial processing. In four children
planing and organising functions were inadequate.
Schooling outcome: at last control six patients at-
tended a college or high school. Five patients served an
apprenticeship or had already finished their professional
training. Four patients had been integrated in a profes-
sional training program for mentally disabled adolescents.
All of the seve children treated after 1993 were going
to the same class as before treatment for GCTC. Of
them three had some concentration difficulties and three
patients had difficulties coping with schooling demands.
Only one patient had severe disabilities that did interfere
with daily life.
In six patients (age at tumour diagnosis 10-16 10/12
years, mean 13 1/12 years) no neuropsychological abnor-
malities or schooling difficulties were reported and
routine neurological examination did not reveal any of
such deficiencies. In these patients no neuropsychologi-
cal testing was performed.
Among this group radiation therapy had been per-
formed in four patients. The applied tumour dose (40-55
Gy, mean 47 Gy) was similar to that of the group of
children with abnormalities in the neuropsychological
testings.
Discussion
With regard to the total number of children with brain
tumour treated at our institution the incidence of GCTC
seems high in comparison to that previously published
from centres in western countries [1-4]. An increasing
incidence of GCTC during the last years (In our series
1980-1992: seven patients, 1993-1997: eight patients)
has been noted by other authors too [1,2]. The incidence
of pediatric brain tumours in general has slightly in-
creased over the last decades [10]. Concerning our series
of GCTC some increase of incidence might be explained
by improved diagnostic procedures as well as the
changes of referral pattern over time.
In agreement to the literature our data demonstrate
an excellent survival outcome for germinomas and benign
teratomas. Modern neurosurgical techniques have mini-
mised damage to brain tissue and have reduced the high
morbidity and mortality associated with past surgical
practices. Furthermore, relapsed patients can be sal-
vaged today by high-dose chemotherapy and autologous
stem cell transplantation [1, 4, 8].
Our results indicate that, in order to reduce late
morbidity, treatment should be tailored to histological
subtype and the spread of the disease. There is discus-
sion about the value of routine adjuvant spinal irradi-
ation in patients with germinoma [2, 4, 11]. Controlled
prospective studies are needed to determine its benefit
versus the attendant risk. Some authors state that
PHCG-producing germinomas have a higher recurrence
rate [8, 12]. Among our patients with J3HCG producing
germinoma (three patients) we saw no relapses although
a test for detection of pHCG in CSF routinely [12] was
not available at our institution.
Histology is still the most important prognostic
factor in GCTC. In an unusual histological diagnosis
one should always be aware of the possibility of a
sampling error in the biopsy. Late tumour relapse in
GCTC is unusual but has been described in teratomas
[2], as demonstrated by one of our patients who suffered
a relapse 92 months after initial diagnosis for multicystic
dermoid tumour. As histology at relapse showed a malig-
nant teratoma it is difficult to deduce retrospectively if
tumour transformation happened, or if the initial biopsy
missed part of the tissue of a mixed germ-cell tumour.
Eight out of ten patients with germinoma and one
patient with malignant teratoma had endocrine abnor-
malities, that were already present in the majority at
diagnosis. Seven out of eight patients with a hypothalamic
tumour developed panhypopituitarism during follow-
up. There is continuing discussion whether radiotherapy
is responsible for worsening pituitary and hypothalamic
function. Most of our patients had already one to three
endocrine axes involved when a CGTC was diagnosed.
Panhypopituitarism emerged during therapy or time of
follow-up in nearly all of them. Follow-up of endocrine
functions is required as most will need lifelong hormone
substitution. In seven patients hyperprolactinemia was
found. With a disruption of hypothalamic-pituitary axis
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after radiotherapy or surgery prolactin secretion is no
longer inhibited [4,13] and in addition to gonadotropine
deficiency this might contribute to hypogonadism and
delayed puberty [14].
In this report seven patients had growth hormone
deficiency. In three patients decreased growth rate had
been documented. Unfortunately not all patients had
been evaluated for growth hormone deficiency, but it is
interesting to note that at last follow-up all patients had
achieved a height above the 10th percentile. The majority
of the patients had radiation therapy after 10 years of
age, thus reducing the possible impact of radiation
therapy on growth.
In our series 5 of 13 surviving patients have to date
no endocrine dysfunction. None of these patients had
tumour infiltrating the thalamic or hypothalamic region.
Two of the patients with a pineal germinoma and without
endocrine dysfunction had radiotherapy with a mean
dose similar to that given to patients with endocrine
dysfunction but without involvement of the pituitary
region. So, here the favourable outcome might be due to
tumour location (pineal gland) and better exclusion of
the pituitary region from irradiation.
At this point we cannot draw any final conclusions as
we could observe in our patients (and according to the
literature) endocrine dysfunction presenting more than
10 years after therapy [13, 15].
Radiation therapy has an impact on neurodevelop-
mental status and IQ, particularly when radiation therapy
is applied before the age of 36 months. Older patients
score lower in schooling outcome after radiation ther-
apy [14, 16]. All but one patients of this series were much
older than three years at time of cranial radiation
therapy but 60% of the patients we studied show neuro-
psychological deficits even years after completing the
treatment. In our series we could not observe any differ-
ence in applied mean radiation dose among patients
with and without neuropsychological sequelae. However,
the impact on IQ and schooling outcome seems to be
less severe in children treated in the last decade in
comparison to data from patients treated with radiation
therapy during the 1980s [14]. For definite conclusions a
longer follow-up is required, but the better outcome
might be due to the reduction of the total applied doses
and the reduced daily fractions of current protocols
[2,16].
In the patients we studied no secondary neoplasms
have to date been observed. Other authors reported (and
predicted for future follow-up) high rates of secondary
neoplasms due to intense radiation therapy [8].
In conclusion, today GCTC in children and adoles-
cents are potentially curable diseases. As a consequence
of tumour site and applied therapy a large proportion
of patients will probably show life long sequelae and
require further care. The aim of modern treatment pro-
tocols is to tailor treatment according to the various
subsets of GCTC. The goal is to increase the cure rate
of the more unfavourable subsets of GCTC (i.e., secret-
ing tumours) and to reduce late sequelae particularly in
those cases with a favourable prognosis (i.e., pure
germinoma). These objectives are followed by the cur-
rent treatment protocol of the International Society of
Paediatric Oncology (SIOP). In the subset of germinoma
two approaches of treatment strategies are compared.
One group of germinoma is treated by a reduced dose of
craniospinal irradiation and tumour boost and the other
group will receive a combination of chemotherapy and
restriction of radiotherapy to the primary site. The
application of radiotherapy in a hyperfractionated
manner might be an additional approach for further
reducing long-term side effects [2, 16]. Achievement of
complete remission of intracerebral germinomas by che-
motherapy alone is possible [3]. However, whether such
an approach of replacing radiotherapy completely by
multiagent chemotherapy might become standard in at
least some subgroups of intracerebral germ-cell tumours
has to be shown in long-term follow-up studies.
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